EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Jw Holdings (096760) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of Jw Holdings KRW 12,975, price KRW 4,325, upside +200.0%, quality 64 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · KR · ISIN KR7096760004

JH Thin data Sep 24, 2026

Jw Holdings

096760 · KO

Clearly undervaluedStrong Fair Value upside, but quality is only moderate.

✓Fair value 12,975 KRW · Strongly undervalued (+200%)
!Quality 64/100
✓Healthy Growth (revenue 5y +4.4 %/yr)
!Thin margins · 7.1% net margin (TTM)
✓Low debt · generates free cash flow
·4.97% dividend yield
✓Ranks above peers (8/10)
!Moderate moat 63/100
!Evidence only low, so the estimate is less certain
!Weak on future: 8 out of 100

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

4,390 KRW 2,324 KRW Fair Value 12,975 KRW Apr 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range 2,324 KRW – 4,390 KRW · fair‑value band 9,731 KRW – 16,219 KRW · the 4,325 KRW price screens below the 12,975 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Sep 24, 2026.

Follow Jw in your weekly email

Every Wednesday you see whether Jw is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

JW Holdings Corporation, together with its subsidiaries, operates as a healthcare company in South Korea, the United States, Japan, China, and internationally.

Show more

JW Holdings Corporation, together with its subsidiaries, operates as a healthcare company in South Korea, the United States, Japan, China, and internationally. The company offers amino acid solutions, gastrointestinal agents, wound care, eye care, liver disease treatment, cold medicine, API, oral and topical analgesic, and other miscellaneous pharmaceutical products. It also offers hairdye, hair care, beauty care, and other cosmetics products; infant care system, gynecological examining table, sterilizer equipment, diagnostic imaging equipment, operating room equipment, non-PVC film, tube, and empty bag, and health supplements. In addition, the company provides integrated services for IV solution. JW Holdings Corporation was founded in 1945 and is based in Gwacheon-si, South Korea.

Stock analysis

Jw Holdings (096760) currently trades at 4,325 KRW, while our model-based Fair Value estimate is 12,975 KRW, implying the stock looks roughly 66.7% undervalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of 19,961 KRW per share, and 23 of the 24 models we run sit above the 4,325 KRW price.

Bear case: the Asset-Based group reads lowest at 2,585 KRW, and 1 of the 24 models stay below the price. Evidence for this calculation is low.

Scenario range: 9,731 KRW (bear) to 16,219 KRW (bull), the price of 4,325 KRW sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 64/100 (solid quality), in the Healthcare sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Jw Holdings reported revenue of 970B KRW in FY2025 versus 789B KRW in FY2021, a compound +5.3%/yr. Reported net income was 58.5B KRW in FY2025.

Key figures

Market cap 299B KRW (≈ $220M) · P/S ratio 0.28 · Dividend yield 5.0% · Net margin 6.0% · Return on equity 22.3% · Return on assets (EBIT) 10.8% · Operating margin 21.2% · Revenue (TTM) 973B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).

What moves the price

The share trades about 1% below its 52-week high and 44% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at 200%, 096760 screens cheaper than that median.

Fair Value models

Bear 9,731 KRW Fair Value 12,975 KRW Bull 16,219 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF 14,631 KRW 19,961 KRW 26,458 KRW 81
Growth DCF 14,699 KRW 19,357 KRW 24,719 KRW 80
Owner Earnings 7,380 KRW 10,097 KRW 13,410 KRW 77
All 24 models by family
DCF Models
FCF DCF 14,631 KRW 19,961 KRW 26,458 KRW 81
Owner Earnings 7,380 KRW 10,097 KRW 13,410 KRW 77
5Y Revenue Exit 17,961 KRW 28,359 KRW 41,452 KRW 72
5Y EBITDA Exit 22,099 KRW 35,963 KRW 51,895 KRW 75
5Y P/E Exit 13,203 KRW 19,615 KRW 26,133 KRW 71
10Y Revenue Exit 15,773 KRW 23,913 KRW 34,494 KRW 66
10Y EBITDA Exit 18,500 KRW 28,383 KRW 41,192 KRW 68
10Y P/E Exit 13,677 KRW 18,774 KRW 24,669 KRW 65
Earnings-Based
Graham-Dodd 5,750 KRW 16,502 KRW 21,763 KRW 65
Lynch FV 3,392 KRW 4,845 KRW 6,299 KRW 61
PEG = 1.0 3,392 KRW 4,845 KRW 6,299 KRW 57
EPV 14,274 KRW 16,006 KRW 17,412 KRW 74
Multiples
P/E Multiple 13,952 KRW 18,602 KRW 23,253 KRW 63
P/S Multiple 10,781 KRW 14,374 KRW 17,968 KRW 58
P/B Multiple 10,781 KRW 14,374 KRW 17,968 KRW 55
EV/EBIT 30,776 KRW 41,090 KRW 51,403 KRW 66
EV/EBITDA 31,940 KRW 42,640 KRW 53,341 KRW 67
EV/Revenue 21,919 KRW 31,383 KRW 40,847 KRW 53
Asset-Based
NCAV (Graham) 1,929 KRW 2,585 KRW 3,858 KRW 54
Growth DCF
Growth DCF 14,699 KRW 19,357 KRW 24,719 KRW 80
Rev-Margin DCF 17,961 KRW 28,417 KRW 40,156 KRW 72
Economic Profit
Residual Income 4,326 KRW 5,756 KRW 17,312 KRW 65
ROIC Compounder 14,780 KRW 17,132 KRW 19,387 KRW 72
Growth Earnings
Growth-Adj P/E 11,177 KRW 15,967 KRW 20,758 KRW 67

Open the full fair value analysis →

Notify me when 096760 reaches fair value

Put 096760 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 64/100

Of which business quality 60 · Market factors (momentum, volatility) 71

Profitability 56
Margins and returns on capital today
Quality Growth 67
Are margins and returns improving?
Cashflow 67
Earnings quality: real cash, not paper profit
Fin. Strength 28
Balance sheet, leverage, solvency risk
Investment 57
Disciplined investing over empire-building
Low Volatility 77
Calm price path (market factor)
Momentum 58
Price trend over the last 3–12 months (market factor)
52W Momentum 86
Distance to the 52-week high (market factor)
Net Issuance 99
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 72/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+9.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.4%
Start year 2020 (pandemic). Over 10 years: +4.5% a year
Revenue growth 18 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.1%
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
≈ +41.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year+36.1%
Dividend (yield on the price)5.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.4% → 17%
⚠ Rate on operating basis: 2025 sits 176% above its own trend.

Growth Forecast

Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−11.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about −13.2% a year for the price.

Watch 096760, get fair value alerts →

Compare Jw Holdings with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 629 stocks

Beats the industry median on 8/10 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 64 · Top 25%
Fair Value upside +200% · Top 25%
Profitability
Return on equity (TTM) 22% · Top 25%
Return on assets 9% · Top 25%
Net margin (TTM) 7% · Above median
Operating margin (TTM) 21% · Top 25%
Growth and dividend
Revenue growth 2% · Below median
Dividend yield (TTM) 5.0% · Top 25%
Balance sheet
Debt / equity 0.31× · Highest 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/FCF 0.0× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 15
FUTURE (revenue growth)8 · sector 20
PAST (return on equity)89 · sector 27
HEALTH (low debt)84 · sector 96
DIVIDEND (yield)99 · sector 32

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Merck KGaA MRK €133.95 €108.70 −19%
Takeda Pharmaceutical Company TAK $18.81 $11.29 −40%
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥45.58 ¥50.14 +10%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,865 ₹1,979 +6%
Galderma Group GALD CHF 163.80 CHF 109.88 −33%
Haleon plc HLN $9.25 $8.50 −8%
Teva Pharmaceutical Industries Limited TEVA $39.01 $20.75 −47%
Sandoz Group SDZ CHF 70.76 CHF 40.16 −43%
Zoetis Inc ZTS $71.61 $108.48 +51%
Hansoh Pharmaceutical Group 3692 HK$35.34 HK$38.87 +10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Jw Holdings Fair Value". https://www.fairvalue-calculator.com/stock/096760

Frequently asked questions

Is Jw Holdings (096760) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 12,975 KRW versus a price of 4,325 KRW, about +200% upside (undervalued).
What is the fair value of 096760?
Our model-based fair value for Jw Holdings is 12,975 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 4,325 KRW.
What is the quality score of 096760?
Jw Holdings has a Quality Score of 64/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Jw Holdings (096760)?
Our model-based price target is the fair value of 12,975 KRW (as of Sep 24, 2026) from 24 valuation models. Cautious scenario 9,731 KRW, optimistic scenario 16,219 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Jw Holdings stock forecast for 2026?
Our models put fair value at 12,975 KRW, about +200% upside versus a price of 4,325 KRW (undervalued). Cautious scenario 9,731 KRW, optimistic scenario 16,219 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Jw Holdings (096760)?
Jw Holdings reported trailing-twelve-month revenue of about 973B KRW (latest available figure, as of Sep 24, 2026).
Does Jw Holdings pay a dividend?
Jw Holdings currently shows a dividend yield of about 4.97% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Jw Holdings (096760)?
For today's price to be fair in a discounted-cash-flow model, Jw Holdings would have to grow free cash flow by -11.4 % per year for five years (discount rate 11.7 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +4.4 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 096760 use?
Our models discount Jw Holdings at 11.7 %: a base by market capitalisation (micro), damped by beta 0.57, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Jw Holdings that is -11.4 % per year a year over ten years, using the same discount rate (11.7 %) and the same formula as our fair value.
How much growth has Jw Holdings (096760) delivered so far?
Over the past 5 years revenue at Jw Holdings grew +4.4 % a year. The price currently implies -11.4 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Jw Holdings (096760) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Jw Holdings (-11.4 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Jw Holdings (096760)?
The free-cash-flow yield on the price is 36.41 %: that much free cash flow Jw Holdings produces per unit of market value. When it exceeds the discount rate of our models (11.7 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Jw Holdings (096760)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Jw Holdings it is 12,975 KRW per share (as of Sep 24, 2026), against a price of 4,325 KRW. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Jw Holdings stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 096760 trades below its calculated fair value: price 4,325 KRW, fair value 12,975 KRW, a gap of about +200% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 096760?
No. The price is what the market pays today (4,325 KRW); the fair value is what the company's own numbers justify (12,975 KRW). For Jw Holdings the two are 8,650 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Jw Holdings worth?
The market values Jw Holdings at about 299B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 4,325 KRW; our models calculate a fair value of 12,975 KRW per share.
What do the bullish and bearish scenarios say about 096760?
Our models span a range for Jw Holdings: cautious scenario 9,731 KRW, base 12,975 KRW, optimistic 16,219 KRW per share (as of Sep 24, 2026, price 4,325 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Jw Holdings (096760)?
Balance-sheet figures for Jw Holdings (as of Sep 24, 2026): return on equity 22.3%, debt of 0.31 per unit of equity. They feed the Quality Score of 64/100, which measures business quality independently of the share price.
How far is 096760 from its 52-week high?
Jw Holdings trades at 4,325 KRW, about 1% below its 52-week high of 4,390 KRW and 44% above the low of 3,008 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 12,975 KRW is for.
Which stocks are comparable to Jw Holdings?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Jw Holdings stock attractive at the current price?
The data as of Sep 24, 2026: price 4,325 KRW, calculated fair value 12,975 KRW (+200%), Quality Score 64/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 096760 calculated?
We run Jw Holdings through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 12,975 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Jw Holdings currently trades 200 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Jw Holdings (096760)?
The closing price on Sep 23, 2026 was 4,325 KRW. Our model-based fair value is 12,975 KRW, about +200% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Jw Holdings right now?
The price is below even our cautious bear case (9,731 KRW). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (64/100) at a price below fair value, the discount is the argument here, not the business quality.

Key figures of Jw Holdings

How large is the market capitalisation of Jw Holdings (096760)?
The market capitalisation of Jw Holdings is 299B KRW (≈ $220M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Jw Holdings (096760)?
The price-to-sales ratio of Jw Holdings is 0.28 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Jw Holdings (096760)?
The dividend yield of Jw Holdings is 5.0%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Jw Holdings (096760)?
The net margin of Jw Holdings is 6.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Jw Holdings (096760)?
The return on equity (ROE) of Jw Holdings is 22.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Jw Holdings (096760)?
On an EBIT basis the return on assets of Jw Holdings is 10.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Jw Holdings (096760)?
The operating margin of Jw Holdings is 21.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Jw Holdings (096760)?
Revenue at Jw Holdings is growing +1.5% versus a year earlier (3y avg +3.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Jw Holdings (096760)?
Earnings per share at Jw Holdings are growing +107% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Jw Holdings (096760) carry?
The net debt of Jw Holdings is 265B KRW (fiscal year 2025, ≈ 2.4 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Jw Holdings in the live analysis

One click puts Jw Holdings on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.